Minova Life Science

Minova life sciences - Pharmaceutical company

Zall-Monte Tablet / Zall Monte KID Tablet

COMPOSITION –

ZALL MONTE TAB – Montelukast Sodium IP 10mg + Levocetirizine Dihydrochloride IP 5mg

Zall-Monte-Kid Tablet – Montelukast Sodium IP 4mg +Levocetirizine Dihydrochloride IP 2.5mg

Montelukast

Drug Class: Leukotriene receptor antagonist

  • Montelukast binds with high affinity to the cysteinyl leukotriene receptors (leukotrienes D4 & E4) that are involved in the inflammatory process that causes asthma & allergic rhinitis symptoms.
  • It inhibits leukotriene physiologic effects without exhibiting any agonist activity.
  • It also effectively inhibits cysteinyl leukotriene receptors and reduces daytime and night-time nasal symptoms of patients with rhinitis.

Levocetirizine

Drug class: II generation Antihistamine

  • Levocetirizine, is a potent second-generation antihistamine known for its comparative efficacy and lower incidence of adverse effects relative to its first-generation counterparts.
  • Levocetirizine 5 mg/d was effective in reducing symptoms of allergic rhinitis; seasonal and perennial and idiopathic urticaria¬†with improving quality of life, with an accepted tolerability profile.

COMBINATION:

    • Leukotriene receptor inhibitors can be added with antihistamines to improve day-time as well as night-time symptomatic relief.
    • Regarding all other allergic rhinitis efficacy endpoints, the combination therapy group experienced greater improvements compared with the montelukast monotherapy group.
    • Montelukast plus levocetirizine was well tolerated, with a safety profile similar to that reported for montelukast monotherapy.
    • The investigators concluded that the fixed-dose combination of montelukast plus levocetirizine was effective and safe for the treatment of perennial allergic rhinitis and asthma.

Explore other products

Scroll to Top